88 related articles for article (PubMed ID: 16473917)
1. The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.
Tenmizu D; Noguchi K; Kamimura H; Ohtani H; Sawada Y
Drug Metab Dispos; 2006 May; 34(5):800-6. PubMed ID: 16473917
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
Tenmizu D; Noguchi K; Kamimura H
Drug Metab Dispos; 2006 Nov; 34(11):1811-6. PubMed ID: 16882764
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor, and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection.
Tenmizu D; Fukunaga Y; Noguchi K; Kamimura H
Biomed Chromatogr; 2004 Nov; 18(9):667-72. PubMed ID: 15386500
[TBL] [Abstract][Full Text] [Related]
4. Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion.
Tenmizu D; Endo Y; Noguchi K; Kamimura H
Xenobiotica; 2004 Sep; 34(9):835-46. PubMed ID: 15742977
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models.
Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
Eur J Pharmacol; 2006 Nov; 550(1-3):166-72. PubMed ID: 17010967
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
Eur J Pharmacol; 2007 Mar; 559(2-3):219-26. PubMed ID: 17250824
[TBL] [Abstract][Full Text] [Related]
7. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
[TBL] [Abstract][Full Text] [Related]
8. Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs.
Whiterock VJ; Morgan DG; Lentz KA; Orcutt TL; Sinz MW
Drug Metab Dispos; 2012 Feb; 40(2):228-31. PubMed ID: 22074769
[TBL] [Abstract][Full Text] [Related]
9. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD
J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
Nakamura A; Hirota T; Sugihara K; Morino A
Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum.
Toque HA; Teixeira CE; Lorenzetti R; Okuyama CE; Antunes E; De Nucci G
Eur J Pharmacol; 2008 Sep; 591(1-3):189-95. PubMed ID: 18593576
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats.
Yoo HH; Kim NS; Im GJ; Kim DH
Acta Pharmacol Sin; 2007 Aug; 28(8):1247-53. PubMed ID: 17640490
[TBL] [Abstract][Full Text] [Related]
14. Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.
Bateman KP; Trimble L; Chauret N; Silva J; Day S; Macdonald D; Dube D; Gallant M; Mastracchio A; Perrier H; Girard Y; Nicoll-Griffith D
J Mass Spectrom; 2006 Jun; 41(6):771-80. PubMed ID: 16705670
[TBL] [Abstract][Full Text] [Related]
15. Identification of human metabolites of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel If channel inhibitor, and investigation of the transporter-mediated renal and hepatic excretion of these metabolites.
Umehara K; Shirai N; Iwatsubo T; Noguchi K; Usui T; Kamimura H
Drug Metab Dispos; 2009 Aug; 37(8):1646-57. PubMed ID: 19439489
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs.
Mise M; Yadera S; Matsuda M; Hashizume T; Matsumoto S; Terauchi Y; Fujii T
Drug Metab Dispos; 2004 Feb; 32(2):240-5. PubMed ID: 14744947
[TBL] [Abstract][Full Text] [Related]
17. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.
Hilli J; Korhonen T; Turpeinen M; Hokkanen J; Mattila S; Laine K
J Clin Pharmacol; 2008 Aug; 48(8):986-94. PubMed ID: 18490497
[TBL] [Abstract][Full Text] [Related]
18. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
Kalgutkar AS; Choo E; Taylor TJ; Marfat A
Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
[TBL] [Abstract][Full Text] [Related]
19. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans.
Akabane T; Tanaka K; Irie M; Terashita S; Teramura T
Xenobiotica; 2011 May; 41(5):372-84. PubMed ID: 21385103
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
